.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AA04_Phenprocoumon.Phenprocoumon

Information

Phenprocoumon is a long-acting vitamin K antagonist used as an oral anticoagulant for the prevention and treatment of thromboembolic disorders. It is widely used in Europe but not in the United States. Its clinical effect is similar to warfarin, but with a longer half-life.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.

References

1. Hermann, SA, et al., & Ziesenitz, VC (2023). Pharmacokinetics of a microdosed cocktail of three direct oral anticoagulants in children with congenital heart defects: study protocol for a single-centre clinical trial (DOAC-Child). BMJ paediatrics open 7(1) –. DOI:10.1136/bmjpo-2022-001662 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36720501

2. Abduljalil, K, et al., & Fuhr, U (2013). Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. Clinical pharmacokinetics 52(5) 359–371. DOI:10.1007/s40262-013-0043-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/23519598

3. Stehle, S, et al., & Fuhr, U (2008). Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clinical pharmacokinetics 47(9) 565–594. DOI:10.2165/00003088-200847090-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18698879

Revisions

• 06/2025 initial generated model